The devil we know: is the use of injectable agents for the treatment of MDR-TB justified?
von Delft, D
von Delft, A
MetadataShow full item record
AbstractFor decades, second-line injectable agents (IAs) have been the cornerstone of treatment for multidrug-resistant tuberculosis (MDR-TB). Although evidence on the efficacy of IAs is limited, there is an expanding body of evidence on the serious adverse events caused by these drugs. Here, we present the results of a structured literature review of the safety and efficacy of IAs. We review the continued widespread use of these agents in the context of therapeutic alternatives-most notably the newer TB drugs, bedaquiline and delamanid-and from the context of human rights, ethics and patient-centered care. We conclude that there is limited evidence of the efficacy of IAs, clear evidence of the risks of these drugs, and that persons living with MDR-TB should be informed about these risks and provided with access to alternative therapeutic options.
- Safety and efficacy of exposure to bedaquiline-delamanid in multidrug-resistant tuberculosis: a case series from France and Latvia.
- Authors: Guglielmetti L, Barkane L, Le Dû D, Marigot-Outtandy D, Robert J, Veziris N, Yazdanpanah Y, Kuksa L, Caumes E, Fréchet-Jachym M
- Issue date: 2018 Mar
- Bedaquiline and delamanid in the treatment of multidrug-resistant tuberculosis: Promising but challenging.
- Authors: Li Y, Sun F, Zhang W
- Issue date: 2019 Feb
- World Health Organization recommendations for multidrug-resistant tuberculosis: should different standards be applied?
- Authors: Cox V, Furin J
- Issue date: 2017 Dec 1
- Tuberculosis treatment and drug regimens.
- Authors: Sotgiu G, Centis R, D'ambrosio L, Migliori GB
- Issue date: 2015 Jan 8
- Combined Use of Delamanid and Bedaquiline to Treat Multidrug-Resistant and Extensively Drug-Resistant Tuberculosis: A Systematic Review.
- Authors: Migliori GB, Pontali E, Sotgiu G, Centis R, D'Ambrosio L, Tiberi S, Tadolini M, Esposito S
- Issue date: 2017 Feb 7